Outset Medical

Outset Medical, Inc. is a medical technology company, which provides dialysis solutions to patients and healthcare providers. Its product Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Outset Medical reports robust Q4 performance and eyes home market growth

Outset Medical's Q4 performance showcased strong growth in Tablo Consoles and revenue, with a focus on expanding home dialysis programs and improving patient experience.
The company's strategic initiatives to manage expenses, reduce inventory levels, and enhance cash flow position it for sustainable growth and operational efficiency.
Challenges lie in meeting revenue guidance, sustaining margin expansion, and optimizing sales force efficiency, while opportunities exist in expanding home programs and leveraging partnerships for growth.
Overall, Outset Medical's performance reflects a balanced approach to growth, operational excellence, and strategic positioning in the dialysis market.

Outset Medical excels in Q1 2023, eyes home dialysis growth

Outset Medical's Q1 2023 performance was robust, with revenue growth and margin expansion surpassing expectations.
The company's focus on innovation, margin improvement, and market expansion positions it well for sustained growth.
Challenges in managing expenses and cash burn require attention, but opportunities in home dialysis and premium offerings offer avenues for future growth.

Outset Medical reports strong Q2 results, eyes sustained growth

Outset Medical delivered robust Q2 2023 results, focusing on revenue growth, margin improvement, and commercial progress in acute and home markets. The company reiterated its revenue guidance for 2023 and expressed confidence in Q4 growth driven by business visibility and network effects.
Despite facing challenges related to FDA compliance and market expansion, Outset Medical showcased strengths in customer base expansion, service margin improvement, and market acceptance of Tablo. The company's commitment to patient and provider autonomy underpins its dedication to delivering quality healthcare solutions.
With opportunities to present economic analysis data, drive utilization in acute care settings, and capitalize on Tablo's value proposition, Outset Medical is poised for sustained growth in 2024. Leveraging market trends and addressing challenges will be key to the company's success in the evolving healthcare landscape.

Outset Medical reports Q3 growth, eyes strategic expansion opportunities

Outset Medical's Q3 performance reflects steady revenue growth and margin expansion, with a focus on strategic growth initiatives.
The company's strengths lie in Tablo's success in both acute and home markets, positioning it for future growth and market expansion.
Challenges include navigating competitive pressures and achieving profitability amidst evolving market dynamics, while opportunities exist in market penetration and strategic growth avenues.

Outset Medical reports strong Q4 earnings, eyes growth opportunities

Outset Medical's Q4 performance was strong, with revenue meeting expectations and showing growth, driven by recurring revenue and expense reductions.
The company's strengths lie in wide market presence, valuable software offerings, unique technology, and effective competitive response strategies.
Challenges include deepening patient census, competitive pressures, transitioning to home dialysis, and maintaining cost efficiency and quality of care.
Opportunities for Outset Medical include revenue growth through software, the shift towards home dialysis, Medicare Advantage support, and payer discussions.

Outset Medical reports Q1 revenue miss, focuses on profitability goals

Outset Medical's Q1 performance showed progress despite revenue challenges, with a focus on cost reduction and profitability.
Strengths lie in successful partnerships, nationwide coverage, and gross margin improvement.
Challenges include revenue impact from delays and the need to balance restructuring with customer experience.
Opportunities include revenue growth in Q2, pipeline expansion, and leveraging technology advantage for innovation.

Outset Medical faces sales transformation challenges amidst revenue softness

Outset Medical's Q2 2024 earnings call highlighted revenue softness from console sales but strength in treatment sales and gross margin performance. The company is undergoing a sales transformation to target mainstream enterprise adopters and expects revenue of approximately $110 million for the year.

Outset Medical reports robust Q3 results and eyes growth opportunities

Outset Medical's Q3 performance showcased revenue growth, margin expansion, and strategic focus on profitability.
While facing challenges in maintaining margins, the company remains optimistic about growth opportunities in various market segments.
Executives highlighted the importance of a conservative outlook and emphasized the strength of their order pipeline and sales transformation progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

SAN JOSE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 2024 Stifel Healthcare conference on Tuesday, November 19, 2024, at 10:20 a.m. Eastern time.

Outset Medical to Present at the 2024 Stifel Healthcare Conference

Outset Medical Inc. (NASDAQ:OM ) Q3 2024 Results Conference Call November 6, 2024 5:00 PM ET Company Participants James Mazzola - Head of Investor Relations Leslie Trigg - President, CEO & Chairman Nabeel Ahmed - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Avi Kohn RBC - Capital Markets Suraj Kalia - Oppenheimer & Co Marie Thibault - BTIG Josh Jennings - TD Cowen Operator Good day, and thank you for standing by. Welcome to the 2024 Third Quarter Outset Medical Conference Call.

Outset Medical Inc. (OM) Q3 2024 Earnings Call Transcript

Outset Medical, Inc. (OM) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.71 per share a year ago.

Outset Medical, Inc. (OM) Reports Q3 Loss, Tops Revenue Estimates

SAN JOSE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2024.

Outset Medical Reports Third Quarter 2024 Financial Results

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=109746&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by October 28, 2024 Deadline to Join Class Action Against Outset Medical, Inc.(OM)

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=109727&wire=1 or contact Joseph E. Levi, Esq.

Investors in Outset Medical, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - OM

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=109608&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Outset Medical, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - OM

NEW YORK CITY, NY / ACCESSWIRE / October 28, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Outset Medical securities between September 15, 2020, and August 7, 2024, inclusive (the "Class Period").

FINAL OM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Outset Medical, Inc. Investors to Join the Class Action Lawsuit!

NEW YORK , Oct. 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Outset Medical, Inc. (NASDAQ: OM). Shareholders who purchased shares of OM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Outset Medical, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - OM

NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ:OM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc. - OM

NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Outset Medical securities between September 15, 2020, and August 7, 2024, inclusive (the "Class Period").

FINAL REMINDER OM DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Outset Medical, Inc. Investors to Participate in the Class Action Lawsuit!

NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outset Medical, Inc. (NASDAQ: OM) between September 15, 2020 and August 7, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline.

OM DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Outset Medical, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action – OM

NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc. - OM

LOS ANGELES , Oct. 25, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM). Class Period: September 15, 2020 – August 7, 2024 Lead Plaintiff Deadline: October 28, 2024 If you wish to serve as lead plaintiff of the Outset Medical lawsuit, you can submit your contact information at www.glancylaw.com/cases/Outset-Medical-Inc-1/.

OM Investors Have Opportunity to Lead Outset Medical, Inc. Securities Fraud Lawsuit

LOS ANGELES, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 28, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM ) securities between September 15, 2020 and August 7, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Outset Medical, Inc. (OM)

Investors can contact the law firm at no cost to learn more about recovering their losses

Outset Medical, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. Oct. 28, 2024 Deadline to file Lead Plaintiff Motion

Outset Medical features patient experience poster presentations at Kidney Week 2024

New Research Highlights Improvements in Quality of Life and Caregiver Experience for Home Hemodialysis Patients Using Tablo

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Outset Medical, Inc. (“Outset Medical” or “the Company”) (NASDAQ: OM) and certain of its officers.

OM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Outset Medical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

/ ACCESSWIRE / October 23, 2024 / NEW YORK, NY / ACCESSWIRE / October 23, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=109493&wire=1 or contact Joseph E. Levi, Esq.

OM LAWSUIT ALERT: Levi & Korsinsky Notifies Outset Medical, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

/ ACCESSWIRE / October 23, 2024 / NEW YORK, NY / ACCESSWIRE / October 23, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=109485&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Outset Medical, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - OM

WILMINGTON, DE / ACCESSWIRE / October 23, 2024 / Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ GS:OM) on behalf of stockholders.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Outset Medical Inc. On Behalf of Shareholders

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Outset Medical, Inc. (NASDAQ: OM).

The Gross Law Firm Notifies Shareholders of Outset Medical, Inc.(OM) of a Class Action Lawsuit and an Upcoming Deadline

/ ACCESSWIRE / October 23, 2024 / NEW YORK, NY / ACCESSWIRE / October 23, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=109464&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of Outset Medical, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - OM

SAN JOSE, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Wednesday, November 6, 2024.

Outset Medical to Report Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

NEW YORK, NY / ACCESSWIRE / October 23, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=109377&wire=1 or contact Joseph E. Levi, Esq.

News for Outset Medical Stock (OM)